2 hours Amgen (NASDAQ:AMGN) Receives Underperform Rating from Robert W. Baird MarketBeat
Robert W. Baird reissued an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday.
Robert W. Baird reissued an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday.